UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Ventyx Biosciences Inc (VTYX)

Ventyx Biosciences Inc (VTYX)
0.9380 x 7 0.9970 x 1
Post-market by (Cboe BZX)
0.9685 +0.0404 (+4.35%) 04/11/25 [NASDAQ]
0.9380 x 7 0.9970 x 1
Post-market 0.9895 +0.0210 (+2.17%) 18:28 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8600
Day High
0.9783
Open 0.9302
Previous Close 0.9281 0.9281
Volume 832,500 832,500
Avg Vol 1,209,700 1,209,700
Stochastic %K 31.28% 31.28%
Weighted Alpha -78.09 -78.09
5-Day Change +0.0287 (+3.05%) +0.0287 (+3.05%)
52-Week Range 0.7830 - 5.6600 0.7830 - 5.6600
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,889
  • Shares Outstanding, K 71,130
  • Annual Sales, $ 0 K
  • Annual Income, $ -135,120 K
  • EBIT $ -148 M
  • EBITDA $ -147 M
  • 60-Month Beta 0.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.26
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.98
  • Most Recent Earnings $-0.41 on 02/27/25
  • Next Earnings Date 05/08/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 199.01% ( -40.06%)
  • Historical Volatility 76.66%
  • IV Percentile 94%
  • IV Rank 22.30%
  • IV High 796.79% on 04/07/25
  • IV Low 27.41% on 08/08/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 219
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 5,058
  • Open Int (30-Day) 5,653

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.48
  • Number of Estimates 5
  • High Estimate -0.45
  • Low Estimate -0.51
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +22.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7830 +23.69%
on 04/07/25
Period Open: 1.4300
1.5000 -35.43%
on 03/12/25
-0.4615 (-32.27%)
since 03/11/25
3-Month
0.7830 +23.69%
on 04/07/25
Period Open: 2.0800
2.3100 -58.07%
on 01/23/25
-1.1115 (-53.44%)
since 01/10/25
52-Week
0.7830 +23.69%
on 04/07/25
Period Open: 4.6000
5.6600 -82.89%
on 06/05/24
-3.6315 (-78.95%)
since 04/11/24

Most Recent Stories

More News
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

VTYX : 0.9685 (+4.35%)
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

VTYX : 0.9685 (+4.35%)
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

VTYX : 0.9685 (+4.35%)
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

VTYX : 0.9685 (+4.35%)
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

VTYX : 0.9685 (+4.35%)
Insider Purchase: CEO AND PRESIDENT of $VTYX (VTYX) Buys 238,248 Shares

Raju Mohan, the CEO AND PRESIDENT of $VTYX ($VTYX), bought 238,248 shares of the company on 11-22-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

VTYX : 0.9685 (+4.35%)
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

VTYX : 0.9685 (+4.35%)
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

VTYX : 0.9685 (+4.35%)
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

VTYX : 0.9685 (+4.35%)
Why Shares of Ventyx Biosciences Are Dropping Tuesday

Investors were unimpressed by the company's trial results for an ulcerative colitis therapy.

PFE : 21.91 (+1.48%)
VTYX : 0.9685 (+4.35%)

Business Summary

Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on advancing new therapies for patients living with inflammatory diseases and autoimmune disorders. The company's clinical stage pipeline includes VTX958, VTX002 and VTX2735. Ventyx Biosciences Inc. is headquartered in...

See More

Key Turning Points

3rd Resistance Point 1.1295
2nd Resistance Point 1.0539
1st Resistance Point 1.0112
Last Price 0.9685
1st Support Level 0.8929
2nd Support Level 0.8173
3rd Support Level 0.7746

See More

52-Week High 5.6600
Fibonacci 61.8% 3.7970
Fibonacci 50% 3.2215
Fibonacci 38.2% 2.6460
Last Price 0.9685
52-Week Low 0.7830

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar